|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Privately Held |
Company Size: |
15 Employees In BC (15 Total)
15 In BC (15 Total)
|
Year Founded: |
2007 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
biopharmaceutical, SSI, immunotherapy, cancer, arthritis
|
|
|
|
Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company that develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer, inflammatory bowel disease (Crohn's disease, ulcerative colitis) and arthritis.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.
Over 250 cancer patients and 10 patients with inflammatory bowel disease (Crohn's and ulcerative colitis) have been treated to-date with SSIs through compassionate use programs, with no significant side effects reported. Animal studies have confirmed the inherent safety and efficacy of this approach. |
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
|
|
|
Aug 31, 2017
|
Qu Biologics Reports Positive Feedback From FDA Reviewers in Response to Pre-Ind Meeting Package
|
|
Aug 24, 2017
|
Qu Biologics Reports Positive Results for Novel Immune Therapy for Ulcerative Colitis Results
|
|
May 30, 2017
|
Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)
|
|
May 4, 2017
|
Qu Biologics Reports High Response and Remission in Anti-TNFa Naïve Patients Treated with Immune Therapy
|
|
Apr 5, 2017
|
Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn's Disease
|
|
Mar 13, 2017
|
Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy
|
|
Nov 28, 2016
|
Qu Biologics Publishes Promising Paper on Novel Treatment for Allergic Airway Disease
|
|
Apr 21, 2016
|
Qu Biologics Closes Private Financing of CDN $4 Million ($23 Million Raised to Date)
|
|
Apr 11, 2016
|
Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI)
|
|
Mar 5, 2015
|
Qu Biologics Named Life Sciences BC Growth Stage Company of the Year
|
|
|
1 - 10 of 16 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
